3 d* p* }5 A, Q0 U7 F
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:- h& Z e3 ^7 A/ W" o) V5 I
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.6 t6 H( T ~5 G- Q* g, \ http://www.ncbi.nlm.nih.gov/pubmed/22968184/ x% q: | j. A0 v. C9 F
9 s& I4 y; e; { @
依维莫司联合吉非替尼抑制非小细胞肺癌细胞系的效果和作用机制" g6 t! g! j$ ^0 d) s. {# Q2 I4 B http://d.wanfangdata.com.cn/Thesis_Y1770447.aspx